30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: TiGenix

4Q13 ChondroCelect revenue: €1.2MM (~US $1.6MM), +38%

 

2013 revenue: ~$5.9MM, +25%

  • 90% of sales attributed to Belgium, the Netherlands
  • Obtained reimbursement in Spain, but was declined in France
  • Growth acceleration expected for 2014 with increasing contribution of sales in U.K. and Spain